二甲双胍对头颈部鳞状细胞癌微环境的影响:机会窗试验
该机会窗试验在诊断活检与手术切除之间给予新诊断头颈部鳞状细胞癌患者二甲双胍,滴定至标准糖尿病剂量2000 mg/天、疗程9天以上,共入组50例、39例完成全疗程。治疗后间质CAV1和GALB表达及肿瘤细胞凋亡显著增加,间质MCT4表达和Ki67增殖无显著变化,癌细胞内乳酸水平增加2.4倍。
要点
- 二甲双胍滴定至2000 mg/天、疗程≥9天,平均疗程13.6天,耐受良好。
- 治疗后间质CAV1(P<0.001)和GALB(P<0.005)显著增加,TUNEL凋亡显著增加(P<0.001)。
- 间质MCT4表达和Ki67增殖无显著变化,癌细胞乳酸水平增加2.4倍(P<0.05)。
核心结论
- 二甲双胍增加间质细胞分解代谢降低的标志物和衰老,并增加癌细胞凋亡。
- 该研究显示二甲双胍调节头颈部鳞状细胞癌微环境的代谢。
研究设计与样本
- 机会窗试验,在诊断活检与手术切除之间给予二甲双胍。
- 研究对象为新诊断头颈部鳞状细胞癌患者,入组50例,39例完成全疗程。
- 二甲双胍滴定至标准糖尿病剂量2000 mg/天,疗程9天或以上。
主要发现
- 二甲双胍耐受良好,平均疗程13.6天。
- 治疗后间质CAV1显著增加(P<0.001),间质GALB显著增加(P<0.005)。
- TUNEL法检测肿瘤细胞凋亡显著增加(P<0.001)。
- 间质MCT4表达无显著变化,Ki67增殖无显著变化。
- 质谱成像显示癌细胞内乳酸水平治疗后增加2.4倍(P<0.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors. STUDY DESIGN: Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full-treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery. METHODS: Immunohistochemistry (IHC) for the metabolic markers caveolin-1 (CAV1), B-galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki-67 IHC, were performed in pre- and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects. RESULTS: Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4-fold postmetformin (P < 0.05), as measured by MSI. CONCLUSION: Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1808-1815, 2017.
引用
- Curry J, Johnson J, Tassone P, et al. Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. Laryngoscope. 2017. PMID: 28185288. doi:10.1002/lary.26489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。